Meropenem
From Wikipedia, the free encyclopedia
 |
|
|
Meropenem
|
|
| Systematic (IUPAC) name | |
| 3-[5-(dimethylcarbamoyl) pyrrolidin-2-yl] sulfanyl-6- (1-hydroxyethyl)-4-methyl-7-oxo- 1-azabicyclo[3.2.0] hept-2-ene-2-carboxylic acid | |
| Identifiers | |
| CAS number | 119478-56-7 |
| ATC code | J01DH02 |
| PubChem | 64778 |
| DrugBank | APRD01097 |
| Chemical data | |
| Formula | C17H25N3O5S |
| Mol. weight | 383.464 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | Approximately 2%. |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup carbapenem.
Meropenem was developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem® and Meronem®.
Unlike imipenem, it is stable to renal dehydrogenase and can therefore be given without cilastatin. It penetrates into the cerebrospinal fluid. Meropenem also has a reduced potential for causing seizures in comparison with imipenem.
 |
This antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
